Results for tag: "Cystic Fibrosis"

Cystic Fibrosis (CF) is a genetic disorder that affects the lungs and other organs. It is the most common life-threatening genetic disorder in the United States, affecting approximately 30,000 people. In the context of pulmonary medicine, CF is a chronic, progressive disease that affects the lungs and other organs, leading to a wide range of symptoms, including difficulty breathing, frequent lung infections, and poor growth. Treatment for CF is focused on managing symptoms and preventing complications. This includes medications to reduce inflammation, antibiotics to treat infections, and airway clearance techniques to help clear mucus from the lungs. In addition, lung transplantation is an option for some patients. The CF market is a rapidly growing segment of the pulmonary medicine market, with a number of companies developing treatments and therapies. These include Vertex Pharmaceuticals, AbbVie, Gilead Sciences, Novartis, and AstraZeneca. Show Less Read more